Hervolution receives investment from Novo Nordisk Foundation

Hervolution is one of the three companies to join the BII Creation House program run by Novo Nordisk Foundation. After a successful Business Acceleration Academy, Hervolution was recommended for the program by an external committee and approved by the BII Board of Directors. In the coming 18 months, Inprother will be part of BioInnovation Institute and develop the company with the main goal of preparing for clinical trials and bringing the research to the market. As part of the BII Creation House, Inprother has received an investment of DKK 10 million by the Novo Nordisk Foundation.

Related news

STEVENGLAZER
SIRION Biotech Licenses Adenovirus Technology to Danish Startup, Hervolution for its Novel Immunotherapy Design Targeting Endogenous Retrovirus (ERV)
Hervolution_Sharon_Glynn
pexels-photo-3786247